Incomplete Financial Disclosure: In the Editorial entitled, “Herpes Zoster in the Age of Focused Immunosuppressive Therapy,” published in the February 18, 2009, issue of JAMA (2009;301:774-775), the financial disclosures were incomplete. They should have appeared as follows: “Dr Whitley reported that he received support from the National Institutes of Health for the conduct of studies on herpes zoster between 1973 and 1996. Clinical trial data on the natural history of herpes zoster since the completion of controlled trials were analyzed through the support of contract N0-1-AI30025. Dr Whitley reported that he also serves on the board of directors of Gilead Sciences and is a consultant to Chimerix, and receives compensation and stock from both companies; has served as a consultant for Fermavir, which was purchased by Inhibitex in 2004, and reports receiving stock and compensation from both companies; has received compensation from GlaxoSmithKline for grand rounds presentations between 2004 and 2005; and served as a consultant to Novartis in 2005. Dr Gnann reported that he serves as a consultant for Merck Inc.”
A letter of apology accompanies this correction. See also accompanying correction.
Incomplete Financial Disclosure in: Herpes Zoster in the Age of Focused Immunosuppressive Therapy. JAMA. 2010;303(8):734. doi:10.1001/jama.2010.111